Back to News
Market Impact: 0.4
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
Source: 247wallst.com
Healthcare & BiotechProduct Launches
A European regulatory endorsement for an oral obesity pill lifted Eli Lilly shares 4% to $1,295, outperforming the broader drug group. The article provides no further details on the endorsement or the pill.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
LLY0.65
More News
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- Jim Cramer says this is the 'magic elixir' driving Tuesday's stock market
- Usio at ld micro main event: growth, leverage and new catalysts
- Factbox-Anthropic’s public benefit fund and how it compares with other big philanthropic efforts
- Jim Cramer's top 10 things to watch in the stock market Tuesday
- A top medical technology stock is trading at a big discount. Here's why I'm buying